Literature DB >> 19732684

Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.

Kathryn E Huber1, Lisa A Carey, David E Wazer.   

Abstract

Gene expression profiling has led to the discovery of 4 distinct molecular subtypes of breast cancer: luminal A, luminal B, basal like, and HER2 enriched. Investigation of these subtypes in women with breast cancer has given insight into the heterogeneous biology and outcomes in patients with locally advanced disease. These subtypes have been found to be predictors for survival, response to systemic therapy, and locoregional recurrence. This review discusses the biology of locally advanced breast cancer and the available data on how molecular subtype may provide information regarding response to treatment and prognosis of women with locally advanced breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732684     DOI: 10.1016/j.semradonc.2009.05.004

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  42 in total

1.  Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival.

Authors:  Qiao Zheng; Sarah M Dunlap; Jinling Zhu; Erinn Downs-Kelly; Jeremy Rich; Stephen D Hursting; Nathan A Berger; Ofer Reizes
Journal:  Endocr Relat Cancer       Date:  2011-07-11       Impact factor: 5.678

2.  Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.

Authors:  Jing Li; Ana M Gonzalez-Angulo; Pamela K Allen; Tse K Yu; Wendy A Woodward; Naoto T Ueno; Anthony Lucci; Savitri Krishnamurthy; Yun Gong; Melissa L Bondy; Wei Yang; Jie S Willey; Massimo Cristofanilli; Vicente Valero; Thomas A Buchholz
Journal:  Oncologist       Date:  2011-12-06

3.  Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

Authors:  H Masuda; T M Brewer; D D Liu; T Iwamoto; Y Shen; L Hsu; J S Willey; A M Gonzalez-Angulo; M Chavez-MacGregor; T M Fouad; W A Woodward; J M Reuben; V Valero; R H Alvarez; G N Hortobagyi; N T Ueno
Journal:  Ann Oncol       Date:  2013-12-18       Impact factor: 32.976

4.  Deep learning with convolutional neural network in the assessment of breast cancer molecular subtypes based on US images: a multicenter retrospective study.

Authors:  Meng Jiang; Di Zhang; Shi-Chu Tang; Xiao-Mao Luo; Zhi-Rui Chuan; Wen-Zhi Lv; Fan Jiang; Xue-Jun Ni; Xin-Wu Cui; Christoph F Dietrich
Journal:  Eur Radiol       Date:  2020-11-23       Impact factor: 5.315

Review 5.  miRNA - Therapeutic tool in breast cancer? Where are we now?

Authors:  Karolina Zaleska
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-26

6.  Advanced Imaging for Precision Medicine in Breast Cancer: From Morphology to Function.

Authors:  Katja Pinker
Journal:  Breast Care (Basel)       Date:  2017-08-29       Impact factor: 2.860

7.  Breast Cancer Molecular Subtype Prediction by Mammographic Radiomic Features.

Authors:  Wenjuan Ma; Yumei Zhao; Yu Ji; Xinpeng Guo; Xiqi Jian; Peifang Liu; Shandong Wu
Journal:  Acad Radiol       Date:  2018-03-08       Impact factor: 3.173

8.  Subtype-Specific Radiation Response and Therapeutic Effect of FAS Death Receptor Modulation in Human Breast Cancer.

Authors:  Chen-Ting Lee; Yingchun Zhou; Kingshuk Roy-Choudhury; Sharareh Siamakpour-Reihani; Kenneth Young; Peter Hoang; John P Kirkpatrick; Jen-Tsan Chi; Mark W Dewhirst; Janet K Horton
Journal:  Radiat Res       Date:  2017-06-09       Impact factor: 2.841

Review 9.  Breast cancer, neoadjuvant chemotherapy and residual disease.

Authors:  Mariana Chávez-MacGregor; Ana María González-Angulo
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

10.  A metabolic prosurvival role for PML in breast cancer.

Authors:  Arkaitz Carracedo; Dror Weiss; Amy K Leliaert; Manoj Bhasin; Vincent C J de Boer; Gaelle Laurent; Andrew C Adams; Maria Sundvall; Su Jung Song; Keisuke Ito; Lydia S Finley; Ainara Egia; Towia Libermann; Zachary Gerhart-Hines; Pere Puigserver; Marcia C Haigis; Elefteria Maratos-Flier; Andrea L Richardson; Zachary T Schafer; Pier P Pandolfi
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.